Literature DB >> 9146853

Effects of age on cardiovascular responses to adrenaline in man.

M White1, F H Leenen.   

Abstract

AIMS: Whereas the effects of ageing on beta-receptor mediated responses have been extensively studied in vitro and in vivo using the beta-adrenoceptor agonist isoprenaline, little is known regarding ageing induced changes in responses to endogenous catecholamines. In the present study, we assessed age-related changes in cardiac responses to the endogenous beta-adrenoceptor agonist adrenaline and the influence of age-related changes in arterial baroreflex function on these responses.
METHODS: Adrenaline alone was infused in 14 young subjects, age 30 +/- 2 years (eight males, six females), and 18 older subjects (six males, 12 females), age 60 +/- 2 years, and together with ganglionic blockade (trimetaphan) in seven young and 11 older subjects. Adrenaline was infused at 3-4 incremental rates, each rate for 8 min. Cardiac function was assessed by echocardiography.
RESULTS: Adrenaline alone, at infusion rates 20-160 ng kg-1 min-1 caused similar increases in heart rate in the two groups. In contrast, adrenaline caused larger increases in stroke volume, ejection fraction, cardiac index and systolic blood pressure and larger decreases in end-systolic wall stress and diastolic blood pressure in the young compared with older subjects. Older females exhibited the smallest increases in stroke volume index and ejection fraction. With concomitant ganglionic blockade, all above cardiovascular responses to adrenaline were similar in the young and older group. Plasma adrenaline increased similarly in the two groups.
CONCLUSIONS: We conclude that ganglionic blockade does not unmask an age-related decrease in cardiovascular responses to adrenaline (in contrast to isoprenaline). A concomitant ageing induced decrease in neuronal uptake (which applies to adrenaline, but not isoprenaline) may explain such a differential effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146853      PMCID: PMC2042753          DOI: 10.1046/j.1365-2125.1997.00561.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  The cardiovascular system.

Authors:  A Moore; A A Mangoni; D Lyons; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  In vitro aged, hiPSC-origin engineered heart tissue models with age-dependent functional deterioration to study myocardial infarction.

Authors:  Aylin Acun; Trung Dung Nguyen; Pinar Zorlutuna
Journal:  Acta Biomater       Date:  2019-05-27       Impact factor: 8.947

4.  Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.

Authors:  Michael Koutouzis; Savvas Nikolidakis; Anestis Grigoriadis; Dimitrios Koutsogeorgis; Zenon S Kyriakides
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Cardiac response to adrenergic stress differs by sex and across the lifespan.

Authors:  Kathleen C Woulfe; Danielle R Bruns; Aykhan Yusifov; Vikram E Chhatre; Jacob M Zumo; Ross F Cook; Benjamin D McNair; Emily E Schmitt
Journal:  Geroscience       Date:  2021-03-02       Impact factor: 7.713

6.  Model-based prediction of the patient-specific response to adrenaline.

Authors:  J Geoffrey Chase; Christina Starfinger; Christopher E Hann; James A Revie; Dave Stevenson; Geoffrey M Shaw; Thomas Desaive
Journal:  Open Med Inform J       Date:  2010-07-29

7.  Effect of adrenaline on serum mid-regional pro-atrial natriuretic peptide and central blood volume.

Authors:  Casper Sejersen; Jonathan J Bjerre-Bastos; Jens P Goetze; Henning B Nielsen; Asger R Bihlet; Niels H Secher
Journal:  Exp Physiol       Date:  2022-08-21       Impact factor: 2.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.